Q & A: Coding for Immunization Against Respiratory Syncytial Virus

The season for increased risk of respiratory syncytial virus (RSV) infection in the United States begins in October and continues through March. This means many practices are beginning to immunize infants against RSV for the 2024–2025 season. This article reviews coding for administration of the monoclonal antibody product, nirsevimab (RSV-mAb; brand name Beyfortus). This article answers questions on correct coding for immunization against RSV infection, including the following: What is the diagnosis code for RSV-mAb administration?What codes are reported for the RSV-mAb product?What codes are reported for RSV-mAb administration?How is administration of the 200-mg dose reported?Are evaluation and management (E/M) services reported separately?What are other billing and coding considerations for RSV-mAb?